Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference
Posted on: Thursday, 30 July 2009, 07:30 CDT
NEW YORK, July 30 /PRNewswire/ -- Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company and a leading developer of oncology compounds directed to cancer stem cell targets, today announced that the Company's CEO, Ivan Bergstein M.D. has been invited to present at the New Frontiers in Cancer Drug Development conference which is part of IBC's Drug Discovery and Development Week in Boston, MA. Dr. Bergstein's presentation, entitled "Developing Drug Candidates Directed to Cancer Stem Cell Targets: Preclinical and Clinical Update" is scheduled for 9:50AM on Wednesday August 5(th) at the World Trade Center/Seaport Hotel in Boston. Dr. Bergstein has also been invited to participate in a panel discussion following the presentations.
Cancer stem cell targeted therapeutics have emerged as the next frontier in the fight against cancer. As such, this field is significantly influencing current decision making with respect to oncology drug development. With this in mind, Dr. Bergstein's presentation will cover novel pre-clinical and clinical development paradigms, including human trial design, of drug candidates that target cancer stem cells. The talk will also feature Stemline's latest clinical data, as well as results from its pre-clinical pipeline and drug discovery platforms.
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human clinical trial. Stemline is also developing a portfolio of biological and small molecule compounds directed at multiple high value cancer stem cell targets of a variety of hematological and solid cancers. Stemline has built a robust discovery platform called "StemScreen(R)" which the Company has utilized to identify multiple compounds that target and impair cancer stem cells. For more information, please visit the Company's website at www.stemline.com.
Stemline Contact: Tom Cirrito, PhD, Director of Operations, Stemline Therapeutics, Inc. Tel: 212-531-5976; Email: tcirrito@stemline.comSOURCE Stemline Therapeutics, Inc.
Source: PR Newswire
Related Articles
- Drug That Targets Vasculature Growth Attacks Aggressive Thyroid Cancer, Mayo Clinic Researchers Report
- Mayo Clinic Study Shows Drug Could Effectively Treat, Prevent the Spread of Breast Cancer
- Cell Therapeutics, Inc. (CTI) Closes PGT305 (PIONEER) Lung Cancer Clinical Trial; New PGT306 Protocol to Be Submitted to FDA By Year End
- Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
- First Three Patients Treated in Adipose Stem and Regenerative Cell Clinical Safety and Feasibility Study for Breast Reconstruction; Represents First Clinical Use of Cytori's Regenerative Cell Processing System
- Cytori Therapeutics Reports Benefit of Adipose Stem and Regenerative Cells in Reconstructive Surgery From Preclinical Study
- Clinical Safety and Feasibility Study Initiated Using Adipose Stem and Regenerative Cells in Breast Reconstruction Procedures
- The Emerging Drug Targets Outlook: An Analysis of Novel Molecular Targets to Develop Innovative New Therapeutics
- ImmunoGen, Inc. Announces Clinical and Preclinical Findings With TAP Compounds to Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds